



High purity, low endotoxin excipients to stabilize biologics for use in parenteral, ophthalmic, or inhalation applications

Our key promises:

- Uncompromised quality
- Security of supply
- Expert support





Uncompromised quality

- BioHale® **high purity and low endotoxin excipients** facilitate the stabilization of biomolecules, thereby reducing the loss of activity and efficacy in your medicines
- Hassle free use and registration of excipients in all markets due to **multi-compendial** specification
- Ensuring quality by producing in state-of-the-art manufacturing facilities, **FDA** inspected and in accordance with **ICH 07**
- DFE Pharma is a reliable and trusted supplier, known for our high-quality product standards, with **proven use** in global leading Covid-19 vaccines

Specifications compliant with Ph. Eur., USP-NF, JP, ChP monographs

Security of Supply

- Smooth supply of BioHale® excipients. Proven track record of delivering on time in full
- Faster delivery of our BioHale® excipients due to local stocks in Europe, the US and Japan
- BioHale® excipients are **independent of raw material variation** as the active purification steps ensure first time right quality
- **Production capacity** available today and tomorrow

Full control of process



Expert support

- We help to **speed up** your developments and lower pressure on R&D teams by providing the right **technical expertise and formulation support**
- Swift and accurate qualification and registration due to availability of global and local quality and regulatory support

Excipient Information Package (EIP) and Self- Assessment Questionnaire (SAQ) available on request



- BioHale® Sucrose
- BioHale® Trehalose Dihydrate

High purity, low endotoxin excipients



Your medicines, our solutions.

Moving to a healthier world.



For more information, please visit https://dfepharma.com/Biopharma









